A detailed history of Dimensional Fund Advisors LP transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 692,792 shares of PBYI stock, worth $2.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
692,792
Previous 605,977 14.33%
Holding current value
$2.07 Million
Previous $1.98 Million 10.58%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$2.25 - $4.03 $195,333 - $349,864
86,815 Added 14.33%
692,792 $1.77 Million
Q2 2024

Aug 09, 2024

BUY
$2.92 - $5.83 $110,037 - $219,697
37,684 Added 6.63%
605,977 $1.98 Million
Q1 2024

May 10, 2024

BUY
$4.29 - $7.4 $302,749 - $522,225
70,571 Added 14.18%
568,293 $3.01 Million
Q4 2023

Feb 07, 2024

BUY
$2.23 - $4.49 $40,610 - $81,767
18,211 Added 3.8%
497,722 $2.16 Million
Q3 2023

Nov 09, 2023

BUY
$2.63 - $4.09 $129,403 - $201,240
49,203 Added 11.43%
479,511 $1.26 Million
Q2 2023

Aug 09, 2023

SELL
$2.6 - $3.58 $59,272 - $81,613
-22,797 Reduced 5.03%
430,308 $1.52 Million
Q1 2023

May 12, 2023

BUY
$2.21 - $4.82 $486,942 - $1.06 Million
220,336 Added 94.66%
453,105 $1.4 Million
Q4 2022

Feb 09, 2023

BUY
$2.12 - $5.08 $371,983 - $891,357
175,464 Added 306.19%
232,769 $984,000
Q3 2022

Nov 10, 2022

BUY
$2.27 - $3.84 $130,082 - $220,051
57,305 New
57,305 $136,000
Q4 2021

Feb 09, 2022

SELL
$2.85 - $6.58 $120,549 - $278,320
-42,298 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$6.63 - $9.39 $66,412 - $94,059
10,017 Added 31.03%
42,298 $297,000
Q2 2021

Aug 12, 2021

BUY
$8.98 - $11.6 $289,883 - $374,459
32,281 New
32,281 $296,000

Others Institutions Holding PBYI

About PUMA BIOTECHNOLOGY, INC.


  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $136M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.